Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Neuralstem Inc. Shares Soared

By Sean Williams - Mar 28, 2014 at 2:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neuralstem shares jumped after reporting another positive study involving its lead pipeline product, NSI-566, in rats. Can shares head even higher?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Neuralstem ( CUR ) a clinical-stage biopharmaceutical company fighting central nervous system disorders with neural stem-cell-based therapies -- spiked higher by as much as 15% after announcing intriguing study results for NSI-566 stem cells and their ability to improve poststroke symptoms in rats.

So what: According to Neuralstem's press release of study results that were also published in peer-reviewed journal, PLOS ONE, ischemic-stroke rats that were transplanted with Neuralstem's experimental NSI-566 cells into their brain "experienced functional improvement," and that the "grafts both survived and differentiated into neurons." The findings also appeared to demonstrate the dosing played an important role in functional improvement, with higher doses yielding better results. Neuralstem notes that there was a statistically significant difference in motor skills and neurological test improvement for rats that received 10,000 cells/ul to 20,000 cells/ul compared to rats that received 5,000 cells/ul.

Now what: As per the norm we have plenty of preclinical and early stage excitement surrounding stem-cell therapies, but many have failed to translate into late-stage success stories be it for safety, efficacy, or simply overbearing government regulations into stem-cell research. Smaller studies like this involving rats is encouraging, but it in no way guarantees success when transferring over the human trials. As I've said previously with Neuralstem, I'd much rather wait for later-stage concrete trial data before getting in an uproar about another stem-cell-based biopharmaceutical company. With that being said, I'll glad monitor it from the sidelines.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seneca Biopharma, Inc. Stock Quote
Seneca Biopharma, Inc.
CUR

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.